Cynata Therapeutics Ltd
51S
Company Profile
Business description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.
Contact
100 Cubitt Street
Level 3
CremorneVIC3121
AUST: +61 370676940
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
2
Stocks News & Analysis
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
stocks
Trouble continues as Star Entertainment burns through cash
More pain in the horizon as the company struggles to stay afloat.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,652.70 | 58.30 | 0.68% |
| CAC 40 | 7,763.97 | 30.47 | 0.39% |
| DAX 40 | 21,003.50 | 13.19 | 0.06% |
| Dow JONES (US) | 43,698.04 | 210.21 | 0.48% |
| FTSE 100 | 8,526.44 | 5.90 | 0.07% |
| HKSE | 20,106.55 | 180.74 | 0.91% |
| NASDAQ | 19,726.32 | 96.12 | 0.49% |
| Nikkei 225 | 39,027.98 | 125.48 | 0.32% |
| NZX 50 Index | 13,052.90 | 35.41 | -0.27% |
| S&P 500 | 6,030.39 | 33.73 | 0.56% |
| S&P/ASX 200 | 8,402.40 | 55.00 | 0.66% |
| SSE Composite Index | 3,242.62 | 1.76 | -0.05% |